Episode 238: 238. What to do With Low Risk Pulmonary Embolism?

Episode 238: 238. What to do With Low Risk Pulmonary Embolism?

Use the PE Severity Index. If low risk and that is the only reason for admission, then the patient is safe for discharge

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60824-6/abstract

https://www.acpjournals.org/doi/10.7326/M23-2442

Avsnitt(387)

Episode 264: 263. Rates of Atrial Fibrillation 12 months After Onset of Hospitalized Transient AF

Episode 264: 263. Rates of Atrial Fibrillation 12 months After Onset of Hospitalized Transient AF

patients who have new-onset transient AF detected during a hospitalization for noncardiac surgery or medical illness and are discharged in sinus rhythm, approximately 1 in 3 have AF detected in the ye...

4 Apr 20247min

Episode 263: 262. Does Omalizumab Help For Peanut Allergy?

Episode 263: 262. Does Omalizumab Help For Peanut Allergy?

Bottom line Omalizumab does seem to improve allergic reactions to peanuts but comes at a steep price tag. Likely only allergist will prescribe this drug but it is worth know about If you know or take ...

3 Apr 20248min

Episode 262: 261. Are Combined Oral Contraceptives Effective for Treating Acne?

Episode 262: 261. Are Combined Oral Contraceptives Effective for Treating Acne?

At ~24 weeks, ~80-90% of females report improvement in their acne with COCs, compared to 50-80% placebo, and 30-50% will have clear-almost clear skin versus 10-40% on placebo. Efficacy appears similar...

2 Apr 20249min

Episode 260: QM on Spring Break

Episode 260: QM on Spring Break

QM on Spring Break-- but do you like the new format? Andrewbuelt@gmail.com

20 Mars 202452s

Episode 261: 260. SGLT2 Summary Recap

Episode 261: 260. SGLT2 Summary Recap

Diabetic patient- Empagliflozin prevents death from cardiovascular causes: NNT 46 per 3.1 yrs ($600 a month, 1 million dollars per life saved)-HFpEF- SGLT2 inhibitors do not prevent death and cost rou...

19 Mars 20246min

Episode 259: 259. EMPULSE Trial- Empagliflozin and Win Ratios

Episode 259: 259. EMPULSE Trial- Empagliflozin and Win Ratios

These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90 days after starting tr...

18 Mars 20249min

Episode 258: 258. SOLOIST-WHF -- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Episode 258: 258. SOLOIST-WHF -- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Primary Outcome: Composite of deaths from cardiovascular causes or hospitalizations and urgent visits for heart failureDeath was not improved!NNT of 5 for hospitalizations and urgent visits -- However...

15 Mars 20249min

Episode 257: 256. EMPEROR-Reduced- Cardiovascular Outcomes with Empagliflozin in Heart Failure

Episode 257: 256. EMPEROR-Reduced- Cardiovascular Outcomes with Empagliflozin in Heart Failure

NNT of 20 to prevent 1 hospitalization at 16 months of follow upThey composite outcome was driven by decrease hospitalizations NOT deathhttps://www.nejm.org/doi/full/10.1056/NEJMoa2022190

14 Mars 20249min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
rss-jossan-nina
inga-beiga-morsor
alska-oss
rss-vuxna-pa-latsas
sexnoveller-deluxe
angestpodden
johannes-hansen-podcast
not-fanny-anymore
rss-viktmedicinpodden
sova-med-dan-horning
brottarbroder
sa-in-i-sjalen
rss-the-house-podcast-3
rss-basta-livet
rss-sjalsligt-avkladd
rss-psykoterapipodden
smartare-fitness-podden
dodsdomar